● AI Equity Research · Healthcare

Biogen Inc. (BIIB)

AI stock analysis · Drug Manufacturers - General · Last analyzed Aug 17, 2026

Compass Score

3.0/5

Call

Hold

Price

$209.83

AI Target

$237.59 +13.2%

AI Analyst Summary

Biogen's bull thesis rests on a dramatic forward earnings recovery — the stock's forward P/E of 12.6x implies the market is pricing in a substantial rebound from a severely depressed trailing earnings base, and 32 analysts broadly maintain a Buy consensus with a $237.59 mean price target. The Alzheimer's franchise (lecanemab/Leqembi) and cost restructuring are key drivers of the expected inflection, while the pipeline offers optionality in rare neurological diseases. The central risk is that the -84.8% YoY earnings collapse reflects deeper structural deterioration rather than transient charges, which the forward estimates may be too optimistic to capture.

Catalysts

Leqembi (lecanemab) commercial ramp — quarterly prescription volume updates and Medicare coverage expansion in upcoming quarters could materially re-rate earnings expectations
Forward earnings inflection in H2 2025 — if management delivers on the implied recovery baked into the 12.6x forward P/E, analyst upgrades and price target increases are likely to follow
Pipeline readouts in rare neurological diseases — late-stage data events expected over the next 12 months could unlock additional revenue streams and reduce dependence on the legacy MS franchise

Fundamentals

Pe Trailing P/E 37.3x / Forward P/E 12.6x · 3.0/5

Trailing P/E of 37.3x looks stretched for a large-cap pharma, but the forward P/E of 12.6x signals a sharp expected earnings recovery. The wide gap reflects a depressed trailing earnings base rather than structural overvaluation.

Peg PEG 5.06 · 1.0/5

PEG of 5.06 is well above the 3.0 threshold that signals poor growth-adjusted value. This is driven by the collapsed trailing earnings base and near-term earnings headwinds, representing a clear red flag on a pure PEG basis.

Analyst Rating Buy consensus (1.8) · 4.0/5

Consensus of 1.8 on the inverted scale maps to a solid Buy, supported by a 24 Buy / 11 Hold / 1 Sell breakdown across 32 analysts. Broad analyst coverage with strong bullish skew is a constructive signal.

Earnings Trend EPS Growth YoY: -84.8% | Revenue Growth: +3.4% · 1.0/5

An -84.8% YoY earnings collapse is a significant red flag, even accounting for one-time charges or pipeline write-downs. Revenue growth of only 3.4% confirms limited top-line momentum, and earnings deterioration is severe enough to warrant a floor score.

Price Target Beat 4 of 4 quarters beat (last 4 quarters only) · 3.0/5

A perfect 4-for-4 EPS beat rate over the most recent four quarters is encouraging, but only four quarters of data are available. Per guidelines, insufficient 8-quarter history caps this at a neutral score of 3.

Management Mixed — consistent near-term beats, but earnings collapse raises concerns · 3.0/5

Management has demonstrated ability to beat near-term EPS estimates consistently, but the -84.8% earnings decline signals significant execution or strategic challenges at a broader level. Capital allocation credibility is mixed given the scale of earnings deterioration.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.